ERBB2 and triple-negative breast carcinoma: A study explored the viability of a gene therapy approach to treat the highly malignant triple-negative breast cancer (TNBC), which lacks the expression of ErbB2/HER2, estrogen, and progesterone receptors, by targeting the Ca2+/CaM-dependent kinase eEF-2K, which was highly expressed in these tumors [141].